Dr Shambo Samrat Samajdar MD DM- Clinical Pharmacology

Call Contact the practice

Dr Shambo Samrat Samajdar MD DM- Clinical Pharmacology MBBS(R G Kar Medical College and Hospital), MD, DM (Clinical Pharmacology), DAAI, PG Dip Endo & Diab

Mon Wed Fri-7 pm
Tues Thurs Sat - 6 pm
Diabetes & Allergy-Asthma Therapeutics Specialty Clinic
Sanito engineering factory complex.beside balaka apartment. Near L G Showroom and MORE at jardabagan
F/F 3 Hatiara Road, Baguiati

Call in this number +91 86177 56992 for appointment and direction

It was a privilege to present at DIAOBECON 2026 – Annual Conference of Diabetes & Obesity, held from 18–20 September 202...
25/09/2026

It was a privilege to present at DIAOBECON 2026 – Annual Conference of Diabetes & Obesity, held from 18–20 September 2026 at Hyatt Regency, Ashram Road, Ahmedabad.

My session, “One Disease, Many Organs: The Silent Progression from Fat to Organ Dysfunction,” focused on an important shift in the way we understand obesity — not simply as excess body weight, but as a chronic, progressive multisystem disease.

The presentation explored how dysfunctional adiposity can affect multiple organs and contribute to interconnected complications including type 2 diabetes, hypertension, obstructive sleep apnoea, cardiovascular disease, MASLD, osteoarthritis, increased cancer risk and mental-health burden.

A central message was that obesity management should move beyond kilograms and BMI towards organ protection, complication prevention and improvement in quality of life. Importantly, increasing degrees of clinically meaningful weight reduction can translate into progressively greater metabolic and hepatic benefits, including improvements in liver enzymes, steatosis and inflammation, NASH resolution and fibrosis regression.

The key takeaway for clinical practice:
Treat obesity early. Treat it as a disease. And evaluate success not only by weight lost, but by health gained across multiple organ systems.

My sincere thanks to Dr Banshi Saboo Sir for the opportunity and to the entire organising team of DIAOBECON 2026 for creating such an excellent academic platform and a memorable scientific meeting. Banshi Saboo

What if HbA1c and weight improve, but the patient can no longer climb stairs?At DIAOBECON 2026, the Annual Conference of...
24/09/2026

What if HbA1c and weight improve, but the patient can no longer climb stairs?

At DIAOBECON 2026, the Annual Conference of Diabetes & Obesity in Ahmedabad, I discussed sarcopenia through a case that raises this question. In diabetes and obesity care, BMI can conceal declining muscle strength, especially during rapid weight loss.

My key messages were to ask about chair rising, stairs and falls; assess strength and function alongside weight; and review appetite and protein intake during incretin therapy. A reduction in lean mass alone does not establish sarcopenia. When function declines, we need to look for reversible causes and combine appropriate nutrition with resistance exercise. The goal is to protect the patient’s independence as metabolic health improves.

Thank you to Dr Banshi Saboo sir Banshi Saboo and the organising team for the opportunity and a memorable meeting.

Happy to deliver my talk, “Allergen Immunotherapy in the Clinical Pharmacology Outpatient Setting: Role, Rationale and P...
23/09/2026

Happy to deliver my talk, “Allergen Immunotherapy in the Clinical Pharmacology Outpatient Setting: Role, Rationale and Patient Selection,” at the Fifth National Conference of the Association of Clinical Pharmacologists, held at NEIGRIHMS, Shillong.

The presentation focused on integrating allergen immunotherapy into the Clinical Pharmacology OPD as a precision-medicine model. Unlike symptomatic treatment alone, allergen immunotherapy can modify the natural course of selected IgE-mediated allergic diseases by inducing allergen-specific immune tolerance.

Key messages included:

• Sensitisation alone is not an indication—test results must correlate with clinically relevant allergen exposure and symptoms.
• Careful patient selection, particularly assessment of asthma control, is central to safety.
• The choice between SCIT and SLIT should consider evidence, standardised extract availability, patient preference, adherence, cost and emergency-care capacity.
• Structured follow-up must include symptom and medication scores, adherence assessment, adverse-event surveillance and periodic clinical audit.
• Clinical pharmacologists can connect rational pharmacotherapy, immunomodulation, pharmacovigilance and shared decision-making within one coordinated service.

A Clinical Pharmacology OPD–led AIT programme can become a safe, auditable and scalable model for interdisciplinary allergy care, training and real-world research in India.

Grateful to the Association of Clinical Pharmacologists and the organisers at NEIGRIHMS, Shillong, for the opportunity to share this clinical model with colleagues and engage in meaningful academic discussion.

PHARMACOVIGILANCE WEEK SPECIAL SCIENTIFIC WEBINARFrom Signal to Safety📅 Today, Wednesday, 23 September 2026🕘 9:00–10:30 ...
23/09/2026

PHARMACOVIGILANCE WEEK SPECIAL SCIENTIFIC WEBINAR

From Signal to Safety

📅 Today, Wednesday, 23 September 2026
🕘 9:00–10:30 PM IST | Online

Key sessions:

• Inaugural Address: Dr V. Kalaiselvan, Secretary-cum-Scientific Director, IPC
• Pharmacovigilance 2.0: Prof. Santanu Tripathi | Chair: Dr Nilima Kshirsagar
• Creatine Under the Pharmacovigilance Lens: Dr Shambo Samrat Samajdar | Chair: Dr Alok Modi
• Obesity Pharmacovigilance: Dr Bharat Saboo | Chair: Prof. Ashok Das
• Expert Panel moderated by Dr Alok Modi and Dr Harsh Hirani

🎟️ Registration is complimentary but mandatory:
👉 https://forms.gle/D3TV9JuFgqT3Nt499

The joining link will be shared with registered participants.

Organised by Association of Clinical Pharmacologists (ACP), with academic partnership from the IPS Clinical Secretariat, SHIFT and MRF.

Recognise the signal. Interpret the evidence. Protect the patient.

From detecting hypoglycaemia to preventing it.It was a privilege to deliver my lecture, “AI & Digital Innovation in Hypo...
22/09/2026

From detecting hypoglycaemia to preventing it.

It was a privilege to deliver my lecture, “AI & Digital Innovation in Hypoglycaemia Forecasting,” at DIAOBECON 2026—the International Conference of Diabetes & Obesity—held from 18–20 September 2026 at Hyatt Regency, Ashram Road, Ahmedabad.

The central question was simple: can digital technology give clinicians and people living with diabetes enough warning to act before glucose becomes dangerously low?

Key messages from the session:

• CGM tells us where glucose is; forecasting estimates where it is heading.

• Prediction becomes clinically meaningful only when it leads to a safe and timely intervention.

• Near-term forecasts can support alerts, Predictive Low-Glucose Suspend and Automated Insulin Delivery.

• Overnight forecasts may enable personalised bedtime planning, while week-ahead models may help identify high-risk patients who require clinical review.

• In the PROLOG trial, Predictive Low-Glucose Suspend reduced time below 70 mg/dL by 31% without increasing mean glucose—demonstrating how prediction can improve outcomes when linked to an effective response.

• AUROC and RMSE alone are insufficient. We must also assess calibration, lead time, false-alert burden, external validation, subgroup performance and meaningful clinical benefit.

• Every hypoglycaemia alert should be interpreted through a clinical pharmacology lens: drug exposure, patient vulnerability and contextual modifiers such as meals, exercise, alcohol, renal function and recent dose changes.

Artificial intelligence should assist, not replace, clinical judgement. Unvalidated dosing recommendations, opaque algorithms and unsupported glucose-measuring devices must be approached cautiously.

The goal is not to predict every low. It is to prevent the next meaningful one.

My sincere gratitude to Dr Banshi Saboo Sir for giving me this opportunity and for arranging such a remarkable academic feast with exceptional warmth and hospitality. Banshi Saboo 🙏

I am also deeply thankful to Dr Alok Modi for his guidance and for helping me learn and develop a deeper understanding of this evolving subject. Alok Dayanidhi Modi 🙏

It was a privilege to speak at HDSCON-11 on “Precision Pharmacotherapy in Cardio-Diabetes: Choosing the Right Drug for t...
19/09/2026

It was a privilege to speak at HDSCON-11 on “Precision Pharmacotherapy in Cardio-Diabetes: Choosing the Right Drug for the Right Phenotype.”

Through five clinical cases, we discussed moving beyond an HbA1c-centred approach to identify the dominant phenotype—ASCVD, heart failure, chronic kidney disease, obesity or glycaemic urgency—and select therapy according to the outcome that matters most.

The central message was simple: precision pharmacotherapy is not about choosing the newest drug, but the right drug, at the right time, for the right patient. Every prescription must also consider dose modification, adverse effects, organ function, hypoglycaemia risk and opportunities for deprescribing.

HDSCON was a warm, academically enriching and truly memorable experience.

My heartfelt gratitude to Joyati Didi, Dr Guruprasad Bhattacharrya Dada and Dr Mridul Bera Dada for the opportunity. 🙏

18/09/2026

The Hidden Health Triangle: Allergy, Obesity and Diabetes

Can allergy, obesity and diabetes be connected? This five-minute patient-awareness podcast explains the hidden links between breathing, body weight, medicines and blood glucose.

Presented by Dr Shambo Samrat Samajdar, DM Clinical Pharmacology, the episode explores:

• Early warning signs of diabetes
• Why obesity is a chronic disease—not a failure of willpower
• When repeated sneezing or wheezing needs evaluation
• The appropriate role of allergen immunotherapy
• How unnecessary systemic steroid use may affect weight and blood glucose
• When allergic symptoms require emergency attention

The key message is simple: do not normalise persistent allergy symptoms, do not stigmatise obesity, and do not wait for diabetes to become symptomatic.

If you find this information useful, share the podcast with your family and community. Subscribe for evidence-based patient education on diabetes, obesity, allergy and safe medicine use.

This video provides general health education and does not replace individual medical consultation. Please consult an appropriately qualified registered medical practitioner for diagnosis or treatment.

Our article published today in The Times of India—Speaking Tree:“When Zero Meets Infinity, Ganesha Appears”By Shambo Sam...
14/09/2026

Our article published today in The Times of India—Speaking Tree:

“When Zero Meets Infinity, Ganesha Appears”

By Shambo Samrat Samajdar and Shashank Joshi

Where Shiva’s stillness meets Shakti’s boundless energy, Ganesha appears as the wisdom that gathers life’s scattered pieces into one meaningful whole. He reminds us that obstacles are not always overcome by force; sometimes, they dissolve when our energies find the right centre.

May Vighnaharta bring clarity to every choice and an auspicious path to every new beginning.

Wishing everyone a blessed and joyful Ganesh Chaturthi! 🙏

https://timesofindia.indiatimes.com/speaking-tree/daily-ecstasy/when-zero-meets-infinity-ganesha-appears/articleshow/134236695.cms

From glucose lowering to outcome modification.It was a privilege to deliver my case-based lecture, “Precision Pharmacoth...
13/09/2026

From glucose lowering to outcome modification.

It was a privilege to deliver my case-based lecture, “Precision Pharmacotherapy in Cardio-Diabetes: Choosing the Right Drug for the Right Phenotype,” at HDSCON-11—the 11th National Conference in Kolkata, themed “Staying Well with Diabetes.”

Through five clinical phenotypes, we explored one central principle:

HbA1c is one coordinate—not the entire therapeutic compass.

Key takeaways:

• Identify the dominant phenotype first: ASCVD, heart failure, CKD, excess adiposity or glycaemic urgency.

• In symptomatic severe hyperglycaemia or catabolism, insulin may be the correct initial rescue—but it need not become permanent therapeutic inertia.

• In established ASCVD, prioritise agents with demonstrated cardiovascular benefit. Tirzepatide is particularly relevant when obesity and glycaemic burden are major drivers, while recognising that metabolic potency and cardiovascular-outcome evidence are not interchangeable.

• In heart failure, an SGLT2 inhibitor is foundational irrespective of HbA1c; avoid therapies that promote fluid retention.

• In albuminuric CKD, layer kidney-protective therapy thoughtfully—ACE inhibitor/ARB, SGLT2 inhibition and, when eligible, finerenone—with close monitoring of eGFR and potassium.

• Every new prescription should trigger a deprescribing and safety review: hypoglycaemia risk, renal suitability, volume status, ketosis education, gastrointestinal tolerability and opportunities to reduce insulin or sulfonylureas.

The practical message was simple:

Name the preventable outcome before naming the glucose-lowering drug.

Beyond the science, HDSCON was a wonderfully warm, personal and memorable experience.

A special mention to our Joyati Didi ❤️ for attending to every little detail with such affection. That personal touch made the meeting truly special.

It was, as always, a pleasure to meet dear seniors—Mridul Da, Guru Da….. So much learning, warmth and so many good memories in one place.
Joyati Bhattacharya Guruprasad Bhattacharya Mridul Bera

Kudos to the entire HDSCON team for creating a meeting where evidence, mentorship and friendship came together so naturally. Grateful to have been a part of it. 🙏

योगः कर्मसु कौशलम्
“Skill in action.”

Address

F/F 3 Hatiara Road Baguiati
Kolkata

Opening Hours

Monday 7pm - 9pm
Tuesday 7pm - 9pm
Wednesday 7pm - 9pm
Thursday 7pm - 9pm
Friday 7pm - 9pm
Saturday 7pm - 9pm

Telephone

+917044212606

Website

Alerts

Be the first to know and let us send you an email when Dr Shambo Samrat Samajdar MD DM- Clinical Pharmacology posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Dr Shambo Samrat Samajdar MD DM- Clinical Pharmacology:

Shortcuts

Share

Category